Schmieder George J, Huang Eugene Y, Jarratt Michael
Park Avenue Dermatology, Orange Park, FL, USA.
J Drugs Dermatol. 2012 Dec;11(12):1483-9.
Photodynamic therapy (PDT) with aminolevulinic acid (ALA) has been shown to be safe and effective in the treatment of actinic keratoses (AKs) of the face and scalp. A recent small study has suggested that ALA-PDT can be effective for AKs of the dorsal hands/forearms. However, studies designed to provide sufficient statistical power to test this hypothesis are lacking in the literature.
To determine and compare the safety and efficacy of blue light ALA-PDT vs blue light placebo vehicle (VEH) in the treatment of AKs of the upper extremities and to evaluate the effect of occlusion after application of ALA vs VEH.
ALA or VEH was applied to both dorsal hands/forearms for the 3-hour incubation period before blue light treatment (10 J/ cm2). One extremity of each subject was covered with occlusive dressing during the incubation period. Treatment was repeated at week 8 if any AK lesions remained.
The median AK lesion clearance rate at week 12 was 88.7% for extremities treated with occluded ALA (ALA+OCC), 70.0% for extremities treated with nonoccluded ALA, 16.7% for extremities treated with occluded VEH (VEH+OCC), and 5.6% for extremities treated with nonoccluded VEH (P<.0001). ALA+OCC resulted in a significantly higher clearance rate compared with the nonoccluded extremity at weeks 8 (P=.0006) and 12 (P=.0029). Thirty-four percent (12/35) of extremities treated with ALA+OCC had complete clearance of lesions at week 12 compared with 0% (0/35) of extremities treated with VEH+OCC (P=.0002). The safety pro!le in this study is consistent with previously reported side effects of the therapy.
Blue light ALA-PDT following a 3-hour incubation appears efficacious for AK clearance of the upper extremities. Incubation using an occlusive dressing significantly increases the efficacy of the procedure and also increases the incidence and severity of some acute inflammatory side effects of PDT.
已证明用氨基酮戊酸(ALA)进行光动力疗法(PDT)治疗面部和头皮的光化性角化病(AK)安全有效。最近一项小型研究表明,ALA-PDT对手背/前臂的AK可能有效。然而,文献中缺乏旨在提供足够统计效力以检验该假设的研究。
确定并比较蓝光ALA-PDT与蓝光安慰剂赋形剂(VEH)治疗上肢AK的安全性和有效性,并评估ALA与VEH应用后封闭的效果。
在蓝光治疗(10 J/cm²)前,将ALA或VEH涂抹于双手背/前臂,进行3小时孵育期。在孵育期,每个受试者的一个肢体用封闭敷料覆盖。如果仍有任何AK病变,在第8周重复治疗。
在第12周时,用封闭ALA治疗的肢体(ALA+OCC)的AK病变清除率中位数为88.7%,用未封闭ALA治疗的肢体为70.0%,用封闭VEH治疗的肢体(VEH+OCC)为16.7%,用未封闭VEH治疗的肢体为5.6%(P<0.0001)。与未封闭肢体相比,ALA+OCC在第8周(P=0.0006)和第12周(P=0.0029)的清除率显著更高。在第12周时,用ALA+OCC治疗的肢体中有34%(12/35)病变完全清除,而用VEH+OCC治疗的肢体为0%(0/35)(P=0.0002)。本研究中的安全性概况与该疗法先前报道的副作用一致。
3小时孵育后的蓝光ALA-PDT对清除上肢AK似乎有效。使用封闭敷料孵育可显著提高该程序的疗效,同时也增加了PDT一些急性炎症副作用的发生率和严重程度。